Abstract: A vehicle body contour-based derailment detection method for a rail vehicle, including: measuring distances between measuring points and rails through a range finder mounted on an underframe of a vehicle body, and calculating a transverse displacement of the current vehicle body in a vehicle body coordinate system; measuring an inclination angle of the current vehicle body in the vehicle body coordinate system through an inclination sensor on the vehicle body; with reference to a size of the vehicle body and distribution positions of the measuring points, as well as the transverse displacement of the current vehicle body in the vehicle body coordinate system and the inclination angle of the vehicle body in the vehicle body coordinate system, obtaining a dynamic outer contour of the vehicle body in the vehicle body coordinate system and converting it into a dynamic outer contour in the rail coordinate system.

Abstract: This application provides a terminal device, including a noise suppression structure, where the noise suppression structure is disposed on the metal middle plate, the noise suppression structure includes a hollow region running through the first surface and the second surface, and the hollow region communicates with the first cavity, so that digital signal noise that uses the first cavity as a transmission medium has a propagation path in a direction toward the antenna, the propagation path passes through the hollow region, and the hollow region is used to suppress the digital signal noise transmitted through the propagation path, so as to prevent antenna operating performance from being affected by the digital signal noise.

Abstract: An isolated antigen binding protein, which includes at least one CDR of a heavy chain variable region and at least one CDR of a light chain variable region and a method to encode an isolated nucleic acid molecule. A vector with the nucleic acid molecule. A cell with the nucleic acid molecule. A pharmaceutical composition with the isolated antigen binding protein. A method for preventing, alleviating or treating a CS-related disease or disorder. A method for detecting C5 in a sample.

Abstract: This disclosure provides crystalline polymorphs of squalamine phosphate, methods of making the same, and methods of treatment using the same.

Abstract: The present invention relates to novel crystalline Forms C, C?, D? and H3 of 5-({[2-amino (4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of preparing the same.

Abstract: An array substrate and a manufacturing method therefor, a display panel, and a backlight module, are provided. The array substrate may comprise a base substrate, a metal wiring layer, a first planarization layer, an electrode layer, a second planarization layer, and a functional device layer stacked in sequence. The electrode layer comprises a metal sub-layer and a conductive sub-layer stacked on one side of the base substrate in sequence; the material of the metal sub-layer comprises a metal or a metal alloy; the conductive sub-layer has an oxidation resistance and covers the metal sub-layer . The functional device layer is disposed on the side of the second planarization layer distant from the base substrate, and comprises a plurality of functional devices electrically connected to the electrode layer.

Abstract: Embodiments of the present invention relate to use of a GP73 inhibitor in preparation of a drug for treating diabetes. In the embodiments of the present invention, the inventor finds that GP73 plays a key role in blood glucose regulation, and in particular, finds that soluble GP73 can specifically bind to glucagon to form a complex, enhances the blood glucose-rising function and gluconeogenesis function of glucagon and prolongs the half-life of glucagon; and finds soluble GP73 can activate the glucose production in liver and/or kidney and a gluconeogenesis signaling pathway in a glucagon-independent manner. Based on the blood glucose regulation effect of the GP73 described above, the inventor also proves through animal experiments: the GP73 inhibitor can reduce the blood glucose level and glycated hemoglobin level of diabetic mice and have a protective effect on islet ? cells, and thereby having the effect of treating diabetes.

Abstract: An apparatus (10) for navigating a hierarchical electronic questionnaire (12) includes at least one electronic processor (20) programmed to: provide (102) a user interface (UI) (27) via which: at least a portion of the hierarchical electronic questionnaire is presented on a display device (24) represented as a tree-based questionnaire map (30) with a plurality of nodes (32) connected by a plurality of branches (34), the nodes of the plurality of nodes corresponding to questions; a user input is received, via at least one user input device (22), indicative of a selection of at least one of the nodes; and the question corresponding to the selected node is displayed and a user input indicative of an answer to the question corresponding to the selected node is received via the at least one user input device; and populate (104) one or more nodes other than the selected node based on the selected node and/or the answer to the question corresponding to the selected node.

Abstract: A touch substrate, a method for manufacturing a touch substrate, and a touch display device are provided. The touch substrate includes: a base substrate having a first surface; a first over coat layer on the first surface; a first touch electrode on the first over coat layer; and a second over coat layer on the first touch electrode, wherein the first touch electrode is located between the first over coat layer and the second over coat layer, and the second over coat layer covers at least the first touch electrode, and wherein an area of at least one of the first over coat layer and the second over coat layer is less than an area of the first surface in the touch area.

Abstract: The present invention provides a lectin-magnetic carrier coupling complex for separating glycosylated exosomes from a clinical sample. The lectin-magnetic carrier coupling complex comprises a magnetic carrier and lectins coupled to the outer side of the magnetic carrier. The lectin-magnetic carrier coupling complex provided by the present invention may rapidly, accurately, and automatically separate glycosylated exosomes from a clinical sample with a high separation efficiency; and the separated exosomes are intact in morphology without rupturing or cracking, may be directly used for liquid detection of glycosylated exosomes, or directly used for immunology-related detection, or directly used for nucleotide sequence detection and analysis after extracting nucleic acids from the exosomes.

Abstract: A method may include providing a substrate having, on a first surface of the substrate, a low dielectric constant layer characterized by a layer thickness. The method may include heating the substrate to a substrate temperature in a range of 200° C. to 550° C.; and directing an ion implant treatment to the low dielectric constant layer, while the substrate temperature is in the range of 200° C. to 550° C. As such, the ion implant treatment may include implanting a low weight ion species, at an ion energy generating an implant depth equal to 40% to 175% of the layer thickness.

Abstract: The present invention relates to a lectin-macromolecular carrier coupling complex for separating glycosylated exosomes from a clinical sample, which comprises a macromolecular carrier and lectins coupled to the outer side of the macromolecular carrier. The complex may simply, conveniently, rapidly, and accurately separate glycosylated exosomes from a clinical sample with a high separation efficiency and a good repeatability; and the separated exosomes are intact in morphology without rupturing or cracking, may be directly used for liquid detection of glycosylated exosomes, or directly used for immunology-related detection, or directly used for gene detection or analysis after extracting related nucleic acids from the exosomes.

Abstract: Provided herein are polymorphs of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, compositions thereof, methods of preparation thereof, and methods of their uses.

Abstract: A non-transitory computer readable medium (107, 127) stores instructions readable and executable by at least one electronic processor (101, 113) operatively connected with a display (105) and at least one user input device (103) to perform a device service support method (200).

Abstract: In an electronic data processing method, a first column and a second column of at least one table are identified which have a one-to-one or one-to-many relationship with fewer than a threshold number of violations of the one-to-one or one-to-many relationship. On a display, possible data errors in the at least one table corresponding to the violations of the one-to-one or one-to-many relationship are indicated. The identifying of the violations may include generating a weighted bipartite graph representing the first and second columns, and detecting the violations using the bipartite graph. The method may further include displaying, on the display, a user interface whereby a user accepts or rejects each indicated violation of the one-to-one or one-to-many relationship.

Abstract: The present disclosure relates to the field of pharmacology, and in particular, to a preparation method of high-purity total ginkgo flavonol glycoside. The preparation method of high-purity total ginkgo flavonol glycoside includes: (1) mixing Ginkgo biloba extract powder and a first alkaline solution, subjecting to dissolution and centrifugation to obtain a supernatant; (2) subjecting the supernatant to separation with an acid-polar coupled macroporous resin column and to purification with a polyamide column, to obtain high-purity total ginkgo flavonol glycoside. The purity of the total ginkgo flavonol glycoside prepared by the preparation method of high-purity total ginkgo flavonol glycoside according to the present disclosure is ?90%, and has good clinical application prospects; the preparation process does not require organic reagents such as petroleum ether and ethyl acetate, which is environmentally friendly; the transfer rate of the total flavonol glycoside is high.

Abstract: Methods of manufacturing memory devices are provided. The methods improve the quality of a selectively deposited silicon-containing dielectric layer. The method comprises selectively depositing a silicon-containing dielectric layer in a recessed region of a film stack. The selectively deposited silicon-containing dielectric layer is then exposed to a high-density plasma and annealed at a temperature greater than 800 ° C. to provide a silicon-containing dielectric film having a wet etch rate of less than 4 ?/min.

Abstract: Various examples are described for defining automations for client devices enrolled with a management service. A computing environment can cause one or more user interfaces to be shown in a display of an administrator device that include at least one field for generating an automation that includes a trigger, a condition, and an action to automatically be performed when the condition is satisfied. The trigger defines a time at which the management service compares the condition to device profiles generated for client devices enrolled with the management service. The user interface can forecast a number of client devices that will be affected or subject to an automation, and can display results of the automation as it is executed in real time.

Abstract: In an example embodiment, a machine-learned model is trained to rank anomaly points in time series data. The model is capable of being applied in parallel to many different time series simultaneously, allowing for a scalable solution for large scale online networks. The model outputs a ranking score for an input anomaly and allows for ranking of anomalies not just in the same time series but anomalies across multiple time series as well. This ranking can then be used to determine how best to present the ranked anomalies to users in a graphical user interface.

Abstract: In an example embodiment, a model is trained to specifically identify reversal points in data and then to rank these reversal points in order of importance. A reversal point shall be defined as a point in which a particular metric, specifically a first order derivative, crosses over from positive to negative or vice-versa. Users are more likely to be interested in abnormal and significant changes in data, and thus the machine-learned model is trained to evaluate a reversal point based on two dimensions: abnormality and significance.